Spectroscopic reassignment and ground state dissociation energy of molecular iodine

Spectroscopic reassignment and ground state dissociation energy of molecular iodin

Permeability of a one-dimensional potential barrier

Permeability of one dimensional potential barrie

Dissociation energy and long-range potential of diatomic molecules from vibrational spacings - The halogens

Dissociation energy and long-range potential of diatomic molecules from vibrational spacings, halogen

Shape resonances and rotationally predissociating levels - The atomic collision time delay functions and quasibound level properties of H2 /Chi /1 Sigma g plus//

Atomic collision time delay functions and quasibound level properties of ground state of molecular hydroge

A molecular superfluid: non-classical rotations in doped para-hydrogen clusters

Clusters of para-hydrogen (pH2) have been predicted to exhibit superfluid behavior, but direct observation of this phenomenon has been elusive. Combining experiments and theoretical simulations, we have determined the size evolution of the superfluid response of pH2 clusters doped with carbon dioxide (CO2). Reduction of the effective inertia is observed when the dopant is surrounded by the pH2 solvent. This marks the onset of molecular superfluidity in pH2. The fractional occupation of solvation rings around CO2 correlates with enhanced superfluid response for certain cluster sizes

Interatomic forces from spectral data, and utilization of potential curves in spectroscopy, scattering and kinetics

Interatomic potentials and dissociation energies of diatomic hydrogen and halogen molecules studied with spectroscopy and potential curve

Hypersymmetry: a Z_3-graded generalization of supersymmetry

We propose a generalization of non-commutative geometry and gauge theories based on ternary Z_3-graded structures. In the new algebraic structures we define, we leave all products of two entities free, imposing relations on ternary products only. These relations reflect the action of the Z_3-group, which may be either trivial, i.e. abc=bca=cab, generalizing the usual commutativity, or non-trivial, i.e. abc=jbca, with j=e^{(2\pi i)/3}. The usual Z_2-graded structures such as Grassmann, Lie and Clifford algebras are generalized to the Z_3-graded case. Certain suggestions concerning the eventual use of these new structures in physics of elementary particles are exposed

Effect of Vascepa (icosapent ethyl) on progression of coronary atherosclerosis in patients with elevated triglycerides (200-499 mg/dL) on statin therapy: Rationale and design of the EVAPORATE study.

Despite reducing progression and promoting regression of coronary atherosclerosis, statin therapy does not fully address residual cardiovascular (CV) risk. High-purity eicosapentaenoic acid (EPA) added to a statin has been shown to reduce CV events and induce regression of coronary atherosclerosis in imaging studies; however, data are from Japanese populations without high triglyceride (TG) levels and baseline EPA serum levels greater than those in North American populations. Icosapent ethyl is a high-purity prescription EPA ethyl ester approved at 4 g/d as an adjunct to diet to reduce TG levels in adults with TG levels >499 mg/dL. The objective of the randomized, double-blind, placebo-controlled EVAPORATE study is to evaluate the effects of icosapent ethyl 4 g/d on atherosclerotic plaque in a North American population of statin-treated patients with coronary atherosclerosis, TG levels of 200 to 499 mg/dL, and low-density lipoprotein cholesterol levels of 40 to 115 mg/dL. The primary endpoint is change in low-attenuation plaque volume measured by multidetector computed tomography angiography. Secondary endpoints include incident plaque rates; quantitative changes in different plaque types and morphology; changes in markers of inflammation, lipids, and lipoproteins; and the relationship between these changes and plaque burden and/or plaque vulnerability. Approximately 80 patients will be followed for 9 to 18 months. The clinical implications of icosapent ethyl 4 g/d treatment added to statin therapy on CV endpoints are being evaluated in the large CV outcomes study REDUCE-IT. EVAPORATE will provide important imaging-derived data that may add relevance to the clinically derived outcomes from REDUCE-IT